Latest Trial Data Shows Potential of BAN2401 in Preventing Cognitive Decline in Early Alzheimer’s

Latest Trial Data Shows Potential of BAN2401 in Preventing Cognitive Decline in Early Alzheimer’s
The latest data from a Phase 2 trial (study 201) demonstrates that BAN2401 can slow cognitive decline, providing additional evidence of its potential as a disease-modifying therapy for Alzheimer's disease, according to Eisai and Biogen, which are jointly developing the investigative therapy. BAN2401 is an engineered antibody designed to specifically bind and neutralize toxic amyloid aggregates, which are well-known contributors of the neurodegenerative process in Alzheimer’s disease. The Phase 2 (study 201) trial (
Subscribe or to access all post and page content.